| Quarter | Score |
|---|---|
| 2022-Q1 | 49.5 |
| 2022-Q3 | 40.8 |
| 2022-Q4 | 50.9 |
| 2023-Q2 | 41.6 |
| 2023-Q3 | 48.8 |
| 2023-Q4 | 36.1 |
| 2024-Q1 | 51.9 |
| 2024-Q2 | 76.0 |
| 2024-Q3 | 57.5 |
| 2024-Q4 | 57.5 |
| 2025-Q1 | 58.5 |
| 2025-Q2 | 89.1 |
| 2025-Q3 | 74.6 |
| 2025-Q4 | 74.5 |
| 2026-Q1 | 74.6 |
| 2026-Q2 | 79.4 |
High consensus with active accumulation at an attractive valuation
Within 0.0% of funds' estimated purchase price
2 of 18 tracked funds hold CBRE. Avg conviction: 1.2%. Net adding. First tracked at $132.30 (current -1.2% vs tracked).
ValueAct Capital has 2.4% in this stock
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| ValueAct Capital | 2.4% | Add |
| Citadel Advisors | 0.0% | Add |